Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Philogen has entered into a second collaboration with AbbVie to discover and develop novel types of armed antibody products.
Subscribe to our email newsletter
Philogen CEO Duccio Neri said: "We are excited to expand our collaboration with AbbVie, a leader in the field of antibody therapeutics.
"The first agreement between the companies focused on osteoarthritis, and we are continuing to explore the shared scientific strengths of both companies.”
No financial details of the agreement were released.